Feasibility of TEC Chemotherapy Combined with Breast-conserving Surgery in the Treatment of Patients with Stage Ⅱ and Ⅲ Breast Cancer
Objective:To investigate the feasibility of TEC chemotherapy combined with breast-conserving surgery in the treatment of patients with stage Ⅱ and Ⅲ breast cancer and its effect on quality of life.Method:A total of 172 patients with stage Ⅱ and Ⅲ breast cancer admitted to Jining Third People's Hospital from February 2018 to February 2020 were selected and divided into the control group(86 cases,conventional modified radical surgery)and the observation group(86 cases,TEC chemotherapy combined with breast-conserving surgery)according to random number table method.The observation group was treated for 3 months,and then the two groups were followed up.The treatment effect during the follow-up period,serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),carbohydrate antigen 19-9(CA19-9),quality of life score before treatment and after 3 months of treatment,recurrence rate,distant metastasis rate and total incidence of adverse reactions during follow-up were compared between the two groups.Result:Compared with before treatment,the levels of serum CEA,CA125,CA153 and CA19-9 in the two groups after 3 months of treatment decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Compared with before treatment,the scores of quality of life in the two groups after 3 months of treatment increased,and those in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Compared with the control group,the total clinical effective rate was higher and the total incidence of complications was lower in the observation group during the follow-up period,the differences were statistically significant(P<0.05).The recurrence rate,distant metastasis rate and the total incidence of adverse reactions in the observation group were lower than those in the control group during the follow-up period,but the differences were not statistically significant(P>0.05).Conclusion:TEC chemotherapy combined with breast-conserving surgery can inhibit the proliferation of tumor cells and improve the quality of life of patients with stage Ⅱ and Ⅲ breast cancer,and the incidence of complications is low.
Breast cancerChemotherapyBreast-conserving surgery
万方数据
维普
